[Trial use of L-dopa associated with a dopa-decarboxylase inhibitor in Parkinson's syndrome].
D000818:Animals; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D004155:Diphenhydramine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D007980:Levodopa / Q000627:therapeutic use*; D010276:Parasympatholytics / Q000627:therapeutic use*; D010302:Parkinson Disease, Secondary / Q000188:drug therapy*; D014282:Trihexyphenidyl / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D006634:Histamine H1 Antagonists; D010276:Parasympatholytics; D007980:Levodopa; D005680:gamma-Aminobutyric Acid; D014282:Trihexyphenidyl; D004155:Diphenhydramine
Esperienze sull'uso dell'L-dopa associato ad un inibitore della dopa-decarbossilasi nela sindrome di Parkinson